Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Instrumental Assessment and Evaluation of Return to Sport in Patients Who Underwent Surgical Treatment for Posterolateral Corner (PLC) Injuries Associated With Anterior Cruciate Ligament (ACL) Injuries.

NCT07935512 is registered in ClinicalTrials.gov with Stefano Zaffagnini as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07935512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Instrumental Assessment and Evaluation of Return to Sport in Patients Who Underwent Surgical Treatment for Posterolateral Corner (PLC) Injuries Associated With Anterior Cruciate Ligament (ACL) Injuries.
Lead sponsor
Stefano Zaffagnini
Phase
Observational
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
September 30, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anterior cruciate ligament (acl), posterolateral corner

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Lysholm Knee Score Minimum 24 months

    The Lysholm Knee Score is a validated assessment tool used to evaluate knee function through 8 items addressing the knee's ability to meet the functional demands of daily activities. It is commonly used to assess surgical outcomes in patients undergoing treatment for knee ligament or meniscal injuries. The total score is calculated by summing the scores of the individual items, ranging from 0 to 100. Scores are classified as follows: Excellent (95-100), Good (84-94), Fair (65-83), and Poor (\<64).

Lead sponsor's other trials

Stefano Zaffagnini, most recent start first.